LT3989962T - Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymui - Google Patents
Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymuiInfo
- Publication number
- LT3989962T LT3989962T LTEPPCT/IB2020/056096T LTIB2020056096T LT3989962T LT 3989962 T LT3989962 T LT 3989962T LT IB2020056096 T LTIB2020056096 T LT IB2020056096T LT 3989962 T LT3989962 T LT 3989962T
- Authority
- LT
- Lithuania
- Prior art keywords
- miglustat
- leucine
- acetyl
- treating
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868383P | 2019-06-28 | 2019-06-28 | |
| US201962931003P | 2019-11-05 | 2019-11-05 | |
| PCT/IB2020/056096 WO2020261230A1 (en) | 2019-06-28 | 2020-06-26 | Combination therapy with acetyl-leucine and miglustat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3989962T true LT3989962T (lt) | 2025-10-10 |
Family
ID=71452519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/IB2020/056096T LT3989962T (lt) | 2019-06-28 | 2020-06-26 | Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymui |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220362189A1 (lt) |
| EP (2) | EP4650003A3 (lt) |
| DK (1) | DK3989962T3 (lt) |
| ES (1) | ES3048174T3 (lt) |
| FI (1) | FI3989962T3 (lt) |
| HR (1) | HRP20251256T1 (lt) |
| HU (1) | HUE073420T2 (lt) |
| LT (1) | LT3989962T (lt) |
| MA (1) | MA56386B1 (lt) |
| MD (1) | MD3989962T2 (lt) |
| PL (1) | PL3989962T3 (lt) |
| PT (1) | PT3989962T (lt) |
| RS (1) | RS67283B1 (lt) |
| SI (1) | SI3989962T1 (lt) |
| SM (1) | SMT202500369T1 (lt) |
| WO (1) | WO2020261230A1 (lt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| MA54289A (fr) * | 2018-12-06 | 2021-10-06 | Intrabio Ltd | Analogues deutérés d'acétyl-leucine |
| CN118409027B (zh) * | 2024-07-02 | 2024-09-10 | 成都市食品检验研究院 | 一种食品中1-脱氧野尻霉素的含量检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201600385T1 (it) | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| CA3033557A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
-
2020
- 2020-06-26 EP EP25193150.7A patent/EP4650003A3/en active Pending
- 2020-06-26 SI SI202030669T patent/SI3989962T1/sl unknown
- 2020-06-26 FI FIEP20736444.9T patent/FI3989962T3/fi active
- 2020-06-26 ES ES20736444T patent/ES3048174T3/es active Active
- 2020-06-26 EP EP20736444.9A patent/EP3989962B1/en active Active
- 2020-06-26 MD MDE20220505T patent/MD3989962T2/ro unknown
- 2020-06-26 DK DK20736444.9T patent/DK3989962T3/da active
- 2020-06-26 HR HRP20251256TT patent/HRP20251256T1/hr unknown
- 2020-06-26 US US17/623,313 patent/US20220362189A1/en active Pending
- 2020-06-26 MA MA56386A patent/MA56386B1/fr unknown
- 2020-06-26 HU HUE20736444A patent/HUE073420T2/hu unknown
- 2020-06-26 RS RS20251006A patent/RS67283B1/sr unknown
- 2020-06-26 PT PT207364449T patent/PT3989962T/pt unknown
- 2020-06-26 PL PL20736444.9T patent/PL3989962T3/pl unknown
- 2020-06-26 SM SM20250369T patent/SMT202500369T1/it unknown
- 2020-06-26 LT LTEPPCT/IB2020/056096T patent/LT3989962T/lt unknown
- 2020-06-26 WO PCT/IB2020/056096 patent/WO2020261230A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4650003A2 (en) | 2025-11-19 |
| EP3989962B1 (en) | 2025-08-27 |
| DK3989962T3 (da) | 2025-10-13 |
| US20220362189A1 (en) | 2022-11-17 |
| FI3989962T3 (fi) | 2025-10-08 |
| SI3989962T1 (sl) | 2025-11-28 |
| HRP20251256T1 (hr) | 2025-12-05 |
| PT3989962T (pt) | 2025-10-09 |
| EP3989962A1 (en) | 2022-05-04 |
| RS67283B1 (sr) | 2025-11-28 |
| MD3989962T2 (ro) | 2025-12-31 |
| MA56386B1 (fr) | 2025-10-31 |
| EP4650003A3 (en) | 2026-01-21 |
| HUE073420T2 (hu) | 2026-01-28 |
| ES3048174T3 (en) | 2025-12-09 |
| PL3989962T3 (pl) | 2025-11-17 |
| MA56386A (fr) | 2022-05-04 |
| SMT202500369T1 (it) | 2025-11-10 |
| WO2020261230A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3989962T1 (sl) | Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja | |
| SG11202001445XA (en) | Engineered dnase enzymes and use in therapy | |
| GB202018667D0 (en) | Photodynamic therapy and diagnosis | |
| HK40127928A (en) | Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| GB202103164D0 (en) | Therapy | |
| GB202004189D0 (en) | Combination therapy | |
| GB202208157D0 (en) | Photodynamic therapy and diagnosis | |
| GB202208170D0 (en) | Photodynamic therapy and diagnosis | |
| GB202208167D0 (en) | Photodynamic therapy and diagnosis | |
| GB202208166D0 (en) | Photodynamic therapy and diagnosis | |
| GB202208165D0 (en) | Photodynamic therapy and diagnosis | |
| GB202208164D0 (en) | Photodynamic therapy and diagnosis | |
| GB202208161D0 (en) | Photodynamic therapy and diagnosis | |
| GB202018672D0 (en) | Photodynamic therapy and diagnosis | |
| GB202018673D0 (en) | Photodynamic therapy and diagnosis | |
| GB202018671D0 (en) | Photodynamic therapy and diagnosis | |
| GB202018668D0 (en) | Photodynamic therapy and diagnosis | |
| GB202018669D0 (en) | Photodynamic therapy and diagnosis | |
| GB202109373D0 (en) | Combination therapy | |
| GB202109375D0 (en) | Combination therapy | |
| GB202117706D0 (en) | Therapy | |
| GB202107713D0 (en) | Combination therapy | |
| GB202015916D0 (en) | Combination therapy | |
| GB202019218D0 (en) | Therapy |